Clinical trials: Respiratory Viral Infections
Influenza, Human
Study to Evaluate the Safety and Immunogenicity of 'IL-YANG Flu Vaccine Quadrivalent Inj' in Healthy Korean Adults
This study evaluates the safety, tolerability and immunogenicity of IL-YANG quadrivalent vaccine versus IL-YANG trivalent vaccine after a single intramuscular administration in healthy Korean males and females 19 to < 65 years of…
- Trial name
- NCT02480998
- Testing
- IL-YANG Flu Vaccine QIV 0.5mL, IL-YANG Flu Vaccine TIV 0.5mL
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Covid-19, Coronavirus Disease 2019
A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19
The main purpose of this phase-1b, multicenter, randomized double-blind, placebo-controlled, trial is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of bempegaldesleukin (BEMPEG; NKTR-214) in…
- Trial name
- NCT04646044
- Testing
- Bempegaldesleukin, Standard of Care
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Nektar Therapeutics
Healthy Participants
A Study to Learn About the Study Medicine PF-07321332 and Ritonavir in Adult Healthy Chinese Participants.
The purpose of this Phase 1 clinical trial is to help us understand how the drug is changed and eliminated from your body after you take it, the safety, and the the extent to which dise effects can be tolerated of PF-07321332…
- Trial name
- NCT05339334
- Testing
- PF-07321332/ritonavir
- Where
- China
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19, SARS-CoV-2
Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise
The purpose of this study is to evaluate the efficacy and safety of intravenous abatacept administered to hospitalized COVID-19 participants with respiratory compromise.
- Trial name
- NCT04472494
- Testing
- Abatacept
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 61 people
- Sponsor
- Bristol-Myers Squibb
SARS-CoV Infection, COVID-19
COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations
Background: Allergic reactions have been reported to occur after vaccination with both the Pfizer-BioNTech COVID-19 Vaccine and Moderna COVID-19 Vaccine.
- Conditions
- SARS-CoV Infection, COVID-19, Allergic Reaction, Mast Cell Disorder
- Trial name
- SARS (NCT04761822)
- Testing
- Moderna COVID-19 Vaccine, Pfizer-BioNTech COVID-19 Vaccine
- Where
- 29 sites in United States
- Volunteers
- 746 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Respiratory Syncytial Virus Infections
Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age
The purpose of this study was to evaluate the infectivity, safety, and immunogenicity of the recombinant live-attenuated respiratory syncytial virus (RSV) vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 when delivered as nose drops to…
- Trial name
- NCT03227029
- Testing
- RSV ΔNS2/Δ1313/I1314L, RSV 276
- Where
- 12 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Immunosuppression, COVID-19
Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations
To determine whether providing a recombinant booster COVID-19 vaccine improves sustained humoral and cell-mediated immunogenicity against SARS-CoV-2 in immunosuppressed patients with Inflammatory Bowel Disease (IBD) and/or solid…
- Trial name
- NCT06027229
- Testing
- NVX-CoV2372
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Wisconsin, Madison
Influenza
Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households
Otherwise healthy index patients (IP) are randomized to either baloxavir marboxil or placebo if their influenza symptoms onset was within 48 hours of screening.
- Trial name
- NCT03969212
- Testing
- Baloxavir Marboxil
- Where
- 142 sites in United States, Bulgaria and 14 more
- Volunteers
- 4,138 people
- Sponsor
- Hoffmann-La Roche
COVID-19, Corona Virus Infection
Pre-exposure Prophylaxis for SARS-Coronavirus-2
Objective: To determine if pre-exposure prophylaxis with hydroxychloroquine is effective for the prevention of COVID-19 disease.
- Conditions
- COVID-19, Corona Virus Infection, ARDS, Acute Respiratory Distress Syndrome
- Trial name
- NCT04328467
- Testing
- Hydroxychloroquine
- Where
- 2 sites in United States
- Volunteers
- 1,483 people
- Sponsor
- University of Minnesota
Influenza
DMID 21-0041; Influenza CVD 59000
The primary objective of EMIT-2 is to use a randomized controlled trial (RCT) design to implement interventions which are known to reduce inhalation (airborne) transmission, so that the contribution of transmission by route of…
- Trial name
- EMIT-2 (NCT05666245)
- Testing
- Personal Protective Equipment (PPE) - Under High Air Hygiene, No Intervention - Under High Air Hygiene, Personal Protective Equipment (PPE) - Under Low Air Hygiene
- Where
- 2 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Influenza
Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok
The purpose of this study was to evaluate a single dose of FluBlok in terms of safety, efficacy and effectiveness in prevention of influenza and influenza-like illness and assess clinical lot-to-lot consistency in manufacturing…
- Trial name
- NCT00539981
- Testing
- FluBlok®
- Where
- 24 sites in United States
- Volunteers
- 4,648 people, healthy volunteers welcome
- Sponsor
- Sanofi
Bronchiolitis, Bronchiolitis, Viral
Nasal and Bronchial Absorption Sampling in RSV Bronchiolitis
This study will compare the novel methods of NS and BS with the standard technique of nasophayngeal aspiration (NPA) and routine ETT suction.
- Conditions
- Bronchiolitis, Bronchiolitis, Viral, RSV Infection, Respiratory Failure
- Trial name
- RSV-SAM (NCT03062917)
- Testing
- Nasal and Bronchial Sampling
- Where
- United Kingdom
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Imperial College Healthcare NHS Trust
Long COVID, Long COVID-19
RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms
This platform protocol is designed to be flexible so that it is suitable for a wide range of settings within health care systems, for remote settings, and in community settings where it can be integrated into COVID-19 programs…
- Conditions
- Long COVID, Long COVID-19, Long COVID19
- Trial name
- NCT05965752
- Testing
- BrainHQ/Active Comparator Activity, BrainHQ, PASC CoRE
- Where
- 24 sites in United States
- Volunteers
- 328 people
- Sponsor
- Duke University
Papillomavirus Infections, Coronavirus Disease (COVID-19)
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
The purpose of this study to evaluate the safety and immunogenicity of a 2-dose regimen of 9vHPV vaccine, where the first dose is administered concomitantly with a first dose of a 2-dose regimen of mRNA-1273 vaccine versus…
- Trial name
- NCT05119855
- Testing
- 9vHPV Vaccine, mRNA-1273 Vaccine
- Where
- 38 sites in United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Covid19, Coronavirus
Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2)
The purpose of this research study is to determine if a drug called fluvoxamine can be used early in the course of the COVID-19 infection to prevent more serious complications like shortness of breath.
- Trial name
- NCT04668950
- Testing
- Fluvoxamine
- Where
- 5 sites in United States, Canada
- Volunteers
- 670 people
- Sponsor
- Washington University School of Medicine
Covid19
COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis
A multicenter, adaptive, randomized platform trial evaluating the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge
- Trial name
- NCT04650087
- Testing
- Apixaban 2.5 MG
- Where
- 121 sites in United States
- Volunteers
- 1,291 people
- Sponsor
- Thomas L. Ortel
Influenza
A Study of MHAA4549A in Combination With Oseltamivir Versus Oseltamivir in Participants With Severe Influenza A Infection
This is a randomized, double-blind, placebo-controlled study that will investigate the safety and clinical activity of a single intravenous (IV) dose of MHAA4549A in adult participants hospitalized with severe influenza A in…
- Trial name
- NCT02293863
- Testing
- MHAA4549A, Oseltamivir
- Where
- 171 sites in Belgium, Brazil and 23 more
- Volunteers
- 168 people
- Sponsor
- Genentech, Inc.
Suspected or Confirmed COVID-19
NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients
This open-label, randomized, and controlled clinical trial aims to determine the feasibility and effectiveness of using NBT-NM108, a novel botanical-based fixed-combination drug, to modulate the gut microbiota and treat…
- Trial name
- COVGUT20 (NCT04540406)
- Testing
- NBT-NM108, Usual Care Only
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Notitia Biotechnologies Company
COVID-19 (Healthy Volunteers)
Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older
The primary objectives of the study were: To describe the neutralizing antibody profile at Day 1, Day 22, and Day 36 of each study intervention group.
- Trial name
- NCT04537208
- Testing
- CoV2 preS dTM-AF03 (low-dose), CoV2 preS dTM-AF03 (high-dose), CoV2 preS dTM-AS03 (low-dose)
- Where
- 11 sites in United States
- Volunteers
- 441 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Evaluate Reactogenicity & Immunogenicity of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults
The present study is designed to evaluate the reactogenicity and immunogenicity of one or two booster administrations of an influenza pandemic candidate vaccine (GSK1562902A) in adults aged between 19 and 61 years, previously…
- Trial name
- NCT00506350
- Testing
- Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose, Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses
- Where
- Belgium
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.